GC Pharma KRW 58.3 billionㆍYuhan KRW 55.7 billion… 10 companies with over KRW 10 billion
Newsmp] Exports of pharmaceutical companies listed on the Korea Exchange increased significantly in the first quarter.
Newsmp compiled the quarterly reports of pharmaceutical companies that are closed accounts in November and December, and it was found that the combined exports of 55 companies jumped 23.7% from the same period last year to KRW 419.3 billion.
The share of exports to total sales also rose 0.3%p from 8.1% in the first quarter of last year to 8.4%.
This is contrary to the significant decrease in pharmaceutical exports in the statistics of Korean exports and imports such as the Korea Customs Service during the same period.
Last year, despite a surge in pharmaceutical exports in major export and import statistics, listed pharmaceutical companies’ exports actually decreased.
Ten companies reported exports of more than KRW 10 billion, and 18 companies including them, exceeded KRW 5 billion.
In particular, GC Pharma exports amounted to KRW 58.3 billion, and Yuhan Corporation also exceeded KRW 50 billion with KRW 55.7 billion.
Dong-A ST entered the KRW 40 billion mark with KRW 40.2 billion, followed by ST Pharm with KRW 32.1 billion, CKD Bio with KRW 31.9 billion, and Hanmi Pharmaceutical with KRW 30.2 billion in exports.
Daewoong Pharmaceutical achieved more than KRW 10 billion in exports with KRW 26.3 billion, Chong Kun Dang Pharmaceutical with KRW 19.4 billion, DongKook Pharmaceutical with KRW 17.7 billion, and Kyongbo Pharmaceutical with KRW 13.2 billion.
Moreover, exports of Yungjin Pharmaceutical, Il-Yang Pharmaceutical, HK Inno.N, JW Pharmaceutical, Korea United Pharmaceutical, Jeil Pharmaceutical, Huons, and Dong Wha Pharm also exceeded KRW 5 billion.
In terms of exports to sales, ST Pharm had the largest share with 86.7%, followed by CKD Bio with 68.1%, accounting for more than half of its sales by exports.
In addition, Kyongbo Pharmaceutical’s exports accounted for more than a quarter of sales with 30.6% and Dong-A ST with 25.7%, while SinSin Pharmaceutical, GC Pharma, Yuhan, Corporation, Yungjin Pharmaceutical, BC World Pharm, DongKook Pharmaceutical, and Shin Poong Pharmaceutical also accounted for more than 10%.
